Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Cinacalcet (ausschl. in der Normgröße N3), ATC H05BX01 f. d. Z. 01.11.26-31.10.28 (zzgl. V.-Option 1x12 Mon)

Section 130a (8) SGB V allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of statutory health insurance. With regard to the relevant legal provisions for the awarding of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned substance Cinacalcet (exclusively in the standard size N3), ATC H05BX01, DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the approval model for the aforementioned substance comes into force for the first time on 01.11.2026 and ends on 31.10.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.